title: What defines the quality of patient care in tinea pedis?
abstract: OBJECTIVE
  The aim of this study has been to evaluate patients with tinea pedis for their demographic data and attitudes affecting the treatment of disease, and to compare the in vitro activity of 10 antifungal agents and to relate them to their in vivo activity.
  
  
  METHODS
  Patients with positive mycological examination were enrolled in the study, and a questionnaire comprised of 22 questions was administered. A mycological culture was carried out for each specimen. The antifungal susceptibility of the subcultured species was determined for griseofulvin, terbinafine, ciclopiroxolamine, fluconazole, ketoconazole, itraconazole, bifonazole, sulconazole, oxiconazole and miconazole with microdilution.
  
  
  RESULTS
  Mycological cultures were carried out from 59 patients and there were 35 positive cultures (59.3%). The dermatophytes were Trichophyton rubrum (n = 25) and Trichophyton mentagrophytes (n = 3). The yeasts were Candida albicans (n = 7), Candida glabrata (n = 1) and Trichosporon (n = 2). In the minimum inhibitory concentration (MIC) study, the mean +/- standard error of the mean (SEM) MICs of the antifungals for T. rubrum were as follows: terbinafine 0.01 +/- 0.003, oxiconazole 0.16 +/- 0.05, sulkonazole 0.31 +/- 0.05, miconazole 0.45 +/- 0.15, itraconazole 0.74 +/- 0.01, ketokonazole 1.03 +/- 0.17, ciclopiroxolamine 1.30 +/- 0.12, bifonazole 1.94 +/- 0.51, griseofulvin 4.87 +/- 0.61, and fluconazole 17.91 +/- 3.67 microg/mL.
  
  
  CONCLUSIONS
  Our study supports that azoles could be used as first-line treatment, as oxiconazole is very effective for both dermatophytes and C. albicans. Correlation between in vitro results and clinical outcomes of cases of dermatophytes is still to be established and interpretive breakpoints defined, in order to increase the quality of patient care in tinea pedis.
authors.affiliation: Department of Family Medicine, Erciyes University Medical Faculty, Kayseri, Turkey. smistik@erciyes.edu.tr
authors.forename: S
authors.initials: S
authors.lastname: Mistik
authors.forename: A
authors.initials: A
authors.lastname: Ferahbas
authors.forename: A N
authors.initials: AN
authors.lastname: Koc
authors.forename: D
authors.initials: D
authors.lastname: Ayangil
authors.forename: A
authors.initials: A
authors.lastname: Ozturk
mesh_terms: D000279:Administration, Cutaneous; D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000935:Antifungal Agents / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use*; D002175:Candida / Q000187:drug effects; D002648:Child; D003695:Delivery of Health Care; D005260:Female; D006801:Humans; D006920:Hygiene; D008297:Male; D008826:Microbial Sensitivity Tests; D008875:Middle Aged; D003904:Mitosporic Fungi / Q000187:drug effects*; D011795:Surveys and Questionnaires; D014008:Tinea Pedis / Q000188:drug therapy* / Q000473:pathology; D014249:Trichophyton / Q000187:drug effects; D014250:Trichosporon / Q000187:drug effects; D014421:Turkey
chemical_list: D000935:Antifungal Agents